Extradomain-B Fibronectin (EDB-FN or EDB) is an oncofetal version of fibronectin, which is expressed in a broad range of adult and pediatric solid tumors. Researchers at St. Jude have designed a chimeric antigen receptor (CAR) that targets EDB (EDB-CAR).
EDB-CAR T cells had potent antitumor activity in preclinical models that mimic human disease. In addition to targeting tumor cells, EDB-CAR T cells also recognized and killed the tumor vasculature. Lastly, infusion of EDB-CAR T cells was well tolerated with no apparent side effect.
In summary, St. Jude researchers have successfully generated EDB-CAR T cells that recognize and kill EDB-positive tumor cells and endothelial cells resulting in potent antitumor activity. While their studies have focused on expressing EDB-CARs in T cells, the designed EDB-CAR could be readily expressed in other immune cells (for example γδ T cells, iNKT cells, NK cells, or macrophages).
Immunotherapy, Extradomain-B Fibronectin (EDB-FN, EDB), chimeric antigen receptor (CAR), cancer, solid tumor, brain tumor, T cell, γδ T cells, iNKT cells, NK cells, macrophages.
Granted Patents or Published Applications
Related Scientific References
We are seeking partners to develop and commercialize this CAR for the adoptive cell therapies with immune cells including CAR T cells, abTCR T cells, gdT cells, NKT cells, NK cells, and/or macrophages. Contact: firstname.lastname@example.org
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.